TIMOLOL MALEATE-EX SOLUTION (EXTENDED RELEASE)

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

TIMOLOL (TIMOLOL MALEATE)

Saatavilla:

SANDOZ CANADA INCORPORATED

ATC-koodi:

S01ED01

INN (Kansainvälinen yleisnimi):

TIMOLOL

Annos:

0.5%

Lääkemuoto:

SOLUTION (EXTENDED RELEASE)

Koostumus:

TIMOLOL (TIMOLOL MALEATE) 0.5%

Antoreitti:

OPHTHALMIC

Kpl paketissa:

5ML

Prescription tyyppi:

Prescription

Terapeuttinen alue:

BETA-ADRENERGIC AGENTS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0131275002; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2006-09-05

Valmisteyhteenveto

_ _
_ _
_T-LO and TIMOLOL MALEATE-EX_
(
_timolol maleate) _
_Page 1 of 27_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
T-LO
Timolol Maleate Ophthalmic Solution
Solution, 0.25%, 0.5% w/v timolol (as timolol maleate), ophthalmic
USP
and
Pr
TIMOLOL MALEATE-EX
Timolol Ophthalmic Gel Forming Solution
Solution (Extended-Release), 0.25%, 0.5% w/v timolol (as timolol
maleate), ophthalmic
Antiglaucoma Preparations and Miotics
Sandoz Canada Inc.
110 rue de Lauzon,
Boucherville, QC,
J4B 1E6
Date of Initial Authorization:
SEP 29, 2017
Date of Revision:
DEC 21, 2023
Submission Control Number:
273147
_ _
_ _
_ _
_T-LO and TIMOLOL MALEATE-EX_
(
_timolol maleate) _
_Page 2 of 27_
RECENT MAJOR LABEL CHANGES
6
Dosage Forms, Strengths, Composition and Packaging
12/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS
...............................................................................................................
4
1.1 Pediatrics
....................................................................................................................
4
1.2 Geriatrics
....................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.................................................................................
5
4.1 Dosing Considerations
................................................................................................
5
4.2 Recommended Dose and Dosage Adjust